Sigyn Therapeutics raises ~$61.5k via three convertible notes at 35% discount

Sigyn Therapeutics, Inc.

Entered three convertible note purchase agreements with Brio Capital, Osher Capital, and Lambda Venture Partners.
Total principal amount of $72,222.21 (~$61,500 net proceeds) at 8% interest per annum.
Notes convertible into common stock at a 35% discount to the lowest traded price over prior 20 trading days.
No warrants issued; issuance exempt under Section 4(a)(2) as sales to sophisticated investors.
Notes have a one-year maturity.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Sigyn Therapeutics, Inc. issued convertible note to Brio Capital Master Fund, Ltd for $22,222.22 principal amount, $20,000.00 gross proceeds.

Security: convertible note
Purchaser: Brio Capital Master Fund, Ltd
Consideration: $22,222.22 principal amount, $20,000.00 gross proceeds

Exact text from the filing

On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Brio Capital Master Fund, Ltd, in the principal amount of $22,222.22, which resulted in gross proceeds of $20,000.00 to the Company.

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Sigyn Therapeutics, Inc. issued convertible note to Osher Capital Partners, LLC for $22,222.22 principal amount, $20,000.00 gross proceeds.

Security: convertible note
Purchaser: Osher Capital Partners, LLC
Consideration: $22,222.22 principal amount, $20,000.00 gross proceeds

Exact text from the filing

On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Osher Capital Partners, LLC, in the principal amount of $22,222.22, which resulted in gross proceeds of $20,000.00 to the Company.

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Sigyn Therapeutics, Inc. issued convertible note to Lambda Venture Partners, LLC for $27,777.77 principal amount, $21,500.00 net proceeds.

Security: convertible note
Purchaser: Lambda Venture Partners, LLC
Consideration: $27,777.77 principal amount, $21,500.00 net proceeds

Exact text from the filing

On February 6, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Lambda Venture Partners, LLC, in the principal amount of $27,777.77, which resulted in net proceeds of $21,500.00 to the Company after the payment of related legal fees.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Osher Capital Partners, LLC valued at $22,222.22 (effective 2026-02-12).

Action: entry
Agreement: equity purchase
Counterparty: Osher Capital Partners, LLC
Value: $22,222.22
Effective: 2026-02-12

Exact text from the filing

On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Osher Capital Partners, LLC, in the principal amount of $22,222.22

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Brio Capital Master Fund, Ltd valued at $22,222.22 (effective 2026-02-12).

Action: entry
Agreement: equity purchase
Counterparty: Brio Capital Master Fund, Ltd
Value: $22,222.22
Effective: 2026-02-12

Exact text from the filing

On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Brio Capital Master Fund, Ltd, in the principal amount of $22,222.22

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Lambda Venture Partners, LLC valued at $27,777.77 (effective 2026-02-06).

Action: entry
Agreement: equity purchase
Counterparty: Lambda Venture Partners, LLC
Value: $27,777.77
Effective: 2026-02-06

Exact text from the filing

On February 6, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Lambda Venture Partners, LLC, in the principal amount of $27,777.77

View on SEC.gov

Browse all equity issuances →

Sigyn Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-007574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.